Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
07/01/2020 07/02/2020 07/03/2020 07/06/2020 07/07/2020 Date
297500 308500 309500 305500 308500 Last
1012033 1134469 760946 759791 1003852 Volume
-2.78% +3.70% +0.32% -1.29% +0.98% Change
Financials
Sales 2020 1 632 B 1,36 B 1,36 B
Net income 2020 500 B 0,42 B 0,42 B
Net cash position 2020 390 B 0,33 B 0,33 B
P/E ratio 2020 82,8x
Yield 2020 0,00%
Sales 2021 2 049 B 1,71 B 1,71 B
Net income 2021 673 B 0,56 B 0,56 B
Net cash position 2021 819 B 0,68 B 0,68 B
P/E ratio 2021 62,2x
Yield 2021 0,00%
Capitalization 41 255 B 34 546 M 34 489 M
EV / Sales 2020 25 285x
EV / Sales 2021 20 138x
Nbr of Employees 908
Free-Float 75,7%
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
06/19SK Biopharmaceuticals prices at top of range for South Korea's biggest IPO in..
RE
06/19South Korea's Genexine begins human trial of coronavirus vaccine
RE
06/19EXCLUSIVE : Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC..
RE
06/11Japan's Takeda to sell some Asia-focused drugs to Celltrion for $278 million
RE
06/11Celltrion Shares Rally After Drug Included in New U.K. Trial for Covid-19 The..
DJ
05/05CELLTRION : Teva and Celltrion Healthcare Announce the Launch of TRUXIMA Injecti..
AQ
04/05Celltrion Inc Shares Rise on Covid-19 Treatment Progress
DJ
03/17CELLTRION : Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA ..
AQ
2019CELLTRION : 3Q Net Profit Rose 13% on Year
DJ
2019CELLTRION : and Lonza Sign Contract to Manufacture Remsima Drug Substance
AQ
2019Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
2019CELLTRION : Partners with the Canadian Biotech Company, iProgen Biotech to Devel..
BU
2019Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
2019SOUTH KOREA'S CELLTRION AIMS TO SET : chairman
RE
2018FDA Approves Herceptin Biosimilar Herzuma
DJ
More news
News in other languages on CELLTRION, INC.
06/19SK Biopharmaceuticals prices at top of range for South Korea's biggest IPO in..
06/19South Korea's Genexine begins human trial of coronavirus vaccine
06/19EXCLUSIVE : Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC..
06/11Tokyo démarre en forte baisse, inquiétudes sur les Etats-Unis
06/11Japan's Takeda to sell some Asia-focused drugs to Celltrion for $278 million
More news
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | A068270 | KR7068270008 | MarketScreener
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 252 529,41 KRW
Last Close Price 308 500,00 KRW
Spread / Highest target 19,9%
Spread / Average Target -18,1%
Spread / Lowest Target -64,3%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.70.44%34 270
LONZA GROUP47.11%41 016
SEATTLE GENETICS, INC.49.18%29 505
IQVIA HOLDINGS INC.-7.04%27 430
INCYTE CORPORATION21.93%23 431
MODERNA, INC.202.40%22 999